BofA analyst Jason Zemansky initiated coverage of Kura Oncology (KURA) with a Buy rating and $31 price target. The clinical-stage biotech is advancing targeted cancer treatments, including lead asset ziftomenib in certain forms of acute myeloid leukemia, the analyst tells investors. While sentiment continues to be weighed on by ziftomenib’s early safety signals, which appears to give rival Syndax’s (SNDX) revumenib a “strong competitive advantage,” BofA sees the rival upside as short-term and views Kura as positioned for long-term success.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KURA:
- Kura Oncology initiated with a Sector Perform at Scotiabank
- Kura Oncology to Report Second Quarter 2023 Financial Results
- Kura Oncology 3.03M share Spot Secondary priced at $11.50
- Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
- Kura Oncology falls almost 6% after announcing $100M common stock offering